Last reviewed · How we verify
(MC-1) Pyridoxal 5'-phosphate
Pyridoxal 5'-phosphate (PLP) is the active form of vitamin B6 that acts as a cofactor for numerous enzymes involved in amino acid metabolism, neurotransmitter synthesis, and homocysteine metabolism.
Pyridoxal 5'-phosphate (PLP) is the active form of vitamin B6 that acts as a cofactor for numerous enzymes involved in amino acid metabolism, neurotransmitter synthesis, and homocysteine metabolism. Used for Homocysteinemia / Elevated homocysteine for cardiovascular risk reduction, Pyridoxine-dependent conditions.
At a glance
| Generic name | (MC-1) Pyridoxal 5'-phosphate |
|---|---|
| Sponsor | Medicure |
| Drug class | Vitamin B6 supplement / Cofactor replacement |
| Target | Pyridoxal kinase substrate; cofactor for aminotransferases and decarboxylases |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Metabolic / Neurology |
| Phase | Phase 3 |
Mechanism of action
PLP serves as an essential coenzyme for transaminases, decarboxylases, and other metabolic enzymes critical for protein metabolism and synthesis of neurotransmitters including serotonin, dopamine, and GABA. By supplementing PLP levels, the drug restores enzymatic function in conditions characterized by B6 deficiency or impaired homocysteine metabolism, potentially reducing cardiovascular and neurological complications.
Approved indications
- Homocysteinemia / Elevated homocysteine for cardiovascular risk reduction
- Pyridoxine-dependent conditions
Common side effects
- Peripheral neuropathy (at high doses)
- Sensory ataxia (at high doses)
- Gastrointestinal upset
Key clinical trials
- Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults (EARLY_PHASE1)
- A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG (PHASE3)
- MATCHED (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics) (PHASE2)
- MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- (MC-1) Pyridoxal 5'-phosphate CI brief — competitive landscape report
- (MC-1) Pyridoxal 5'-phosphate updates RSS · CI watch RSS
- Medicure portfolio CI